Study in frontiers in neurology affirms amyloid blood test can help identify patients who may forgo imaging evaluation for alzheimer's disease

Findings suggest the test can reduce the need for pet imaging in some patients with mild cognitive decline to enable therapeutic focus on non-alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs secaucus, n.j. , march 26, 2024 /prnewswire/ -- a blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that alzheimer's disease (ad) is likely not the cause of patients' mild cognitive impairment, finds a new study published in frontiers in neurology  by researchers from quest diagnostics (nyse: dgx), the university of florida and mount sinai medical center in miami beach.
DGX Ratings Summary
DGX Quant Ranking